Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03647488 · ClinicalTrials.gov registry record · Phase 2

Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer

A Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
18
Enrollment target
8
Study locations

NCT03647488 is a Phase 2 study of Carcinoma, Non-Small Cell Lung that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 18 participants, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (94% lower). The trial reports 8 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03647488, a Phase 2 study of Carcinoma, Non-Small Cell Lung, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
18 participants
Enrollment target
8
Study locations

Study Summary

The purpose of this trial was to evaluate the safety and efficacy of capmatinib in combination with spartalizumab in adult participants with epidermal growth factor receptor (EGFR) wild type (for exon 19 deletions and exon 21 L858R substitution mutations), anaplastic lymphoma kinase (ALK) rearrangement negative in locally advanced (stage IIIB, not eligible for definitive chemo-radiation) or metastatic (stage IV) Non-small cell lung cancer (NSCLC) after failure of platinum doublet and checkpoint inhibitor treatment.

Conditions Studied

Carcinoma, Non-Small Cell Lung

Interventions

  • DRUG Docetaxel
  • DRUG Capmatinib
  • DRUG Spartalizumab

Study Locations (8)

Other

  • Novartis Investigative Site - Leuven
  • Novartis Investigative Site - Grenoble
  • Novartis Investigative Site - Lille Cédex
  • Novartis Investigative Site - Cologne
  • Novartis Investigative Site - Tel Aviv
  • Novartis Investigative Site - Madrid

Arkansas

  • Highlands Oncology Group - Fayetteville

Catalonia

  • Novartis Investigative Site - Barcelona

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2018-12-26
Est. Completion 2020-09-07
Phase Phase 2

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03647488

The ClinicalTrials.gov registry entry for NCT03647488 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (94% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 3 interventions - of which Docetaxel is the first listed.

NCT03647488 reports 8 study locations spanning 3 distinct geographic areas - top geographies include Other, Arkansas, Catalonia.

Frequently Asked Questions

What is clinical trial NCT03647488 about?

NCT03647488 is a clinical study titled "Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer". The purpose of this trial was to evaluate the safety and efficacy of capmatinib in combination with spartalizumab in adult participants with epidermal growth factor receptor (EGFR) wild type (for exon 19 deletions and exon 21 L858R substitution mutations), anaplastic lymphoma kinase (ALK) rearrangem...

What is the current status of trial NCT03647488?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2018-12-26. Estimated completion is 2020-09-07.

What conditions does trial NCT03647488 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

What interventions are being tested in trial NCT03647488?

The interventions under investigation include: Docetaxel (DRUG), Capmatinib (DRUG), Spartalizumab (DRUG).

Who is sponsoring clinical trial NCT03647488?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03647488 being conducted?

This trial has 8 study locations across Arkansas, Catalonia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.